Study to Evaluate the Efficacy and Safety of DWP14012 on Maintaining Healing in Subjects With Healed Erosive Esophagitis

Phase 3 Unknown 406 enrolled Daewoong Pharmaceutical Co. LTD.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study aims to demonstrate the noninferiority of DWP14012 to Lansoprazole 15 mg in the maintenance effect of treatment and confirm the safety of DWP14012 in patients with healed erosive esophagitis confirmed on EGD after medication treatment.

Timeline

Start: 2020-07-02
Primary completion: 2021-08-30
Completion: 2021-12-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ABEPRAZAN	Small molecule	20 mg	Oral
Comparator	Lansoprazole	Other / unclassified	15 mg	Oral

Study to Evaluate the Efficacy and Safety of DWP14012 on Maintaining Healing in Subjects With Healed Erosive Esophagitis

Summary

Timeline

Drugs

Indications